CNS Pharmaceuticals, Inc. announced that it has entered into a Securities Purchase Agreement with institutional investors for the sale by the Company of 336,000 shares of the Company?s common stock, par value $0.001 per share, and pre-funded warrants to purchase 30,000 shares of common stock in lieu thereof combined purchase price of one share of common stock and accompanying Common Warrant is $3.75 for the aggregate gross proceeds of $1,372,500 before deducting the financial advisor fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Common Warrants on June 14, 2024. The transaction is expected to close on June 17, 2024.